Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Research Awards

Prof. Hou-Qun Ying | Toxicology and Pharmaceutical Science | Research Excellence Award 

The Second Affiliated Hospital of Nanchang University | China

Dr. Hou-Qun Ying, PhD, born on July 18, 1985, in Shangrao, Jiangxi Province, China, is an accomplished clinical scientist specializing in cancer biomarkers, inflammation-related indices, molecular epidemiology, and therapeutic response prediction. He currently serves as the Vice Director of the Department of Clinical Laboratory Medicine at The Second Affiliated Hospital of Nanchang University, where he plays a leading role in translational research, diagnostic innovation, and clinical laboratory management. Dr. Ying earned his Ph.D. in Clinical Laboratory Diagnosis from Southeast University (2013–2016), after completing his Master of Medicine in Pathogenic Biology at Dali University and his Bachelor of Medicine in Medical Laboratory Science from Tianjin Medical University. His academic and professional journey reflects strong expertise in cancer diagnostics, genetic polymorphisms, biomarker development, and precision medicine. Dr. Ying has successfully led multiple competitive research grants, including the National Natural Science Foundation of China Youth Fund (2018–2020), exploring Hippo-pathway-related genetic variations and EGFR-TKI resistance in non-small cell lung cancer, and the 2024–2027 Regional Fund focusing on SP1 transcription factor–related genetic variations as biomarkers for bevacizumab resistance in metastatic colorectal cancer. His research contributions span more than 70 peer-reviewed publications, with many as first, co-first, or corresponding author in high-impact journals such as Scientific Reports, Oncotarget, Cancer Medicine, Therapeutic Advances in Medical Oncology, Frontiers in Oncology, Pharmacological Research, Biomarkers, Future Oncology, and J Inflammation Research. His studies have provided pivotal insights into inflammatory markers such as fibrinogen-to-pre-albumin ratio, albumin-to-fibrinogen ratio, dNLR, PLR, and novel composite biomarkers for cancer prognosis, treatment response prediction, early diagnosis, and recurrence risk stratification. He has also made influential contributions to colorectal cancer, gastric cancer, gallbladder carcinoma, hepatocellular carcinoma, and NSCLC through biomarker innovation, clinical prediction models, and meta-analytic evaluations. As a corresponding author, Dr. Ying has developed and validated numerous inflammation-based and genetic biomarker signatures, such as FPR, ADS score, MLPAS, CCMLP, and chronic inflammation indices, improving precision therapeutic decisions for chemotherapy, bevacizumab, 5-FU–based regimens, and TKIs. Additionally, his collaborative work extends to machine learning applications in early gastric cancer prediction, molecular mechanisms underlying cancer progression, and multi-omics approaches. With a distinguished record of scientific leadership, grant success, and impactful publications, Dr. Ying continues to advance clinical oncology diagnostics and personalized treatment strategies through rigorous research, innovation, and interdisciplinary collaboration.

Profiles: Scopus | Orcid

Featured Publications

Peng, Y., Shang, R., Wang, Z.-J., Ye, Q.-Y., Tang, X.-Y., Cheng, X.-X., & Ying, H.-Q. (2025). Chronic inflammatory comprehensive signature predicts oxaliplatin and 5-fluorouracil benefit in early colorectal cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/DDDT.S556619

Lu, Y., Ye, Q.-Y., Mei, O., Li, Y.-N., Peng, Y., Ying, H.-Q., & Cheng, X.-X. (2025). Chronic inflammation index-based tumor subsite classification correlated with chemotherapy benefit and survival outcomes in stage II–III colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S517378

Ye, Q.-Y., Wang, Y.-Y., Wang, Z.-J., Lu, M., Peng, H.-X., Wang, X., Cheng, X.-X., & Ying, H.-Q. (2025). Robust predictive performance of MLPAS and CCMLP for clinical outcome and risk stratification in patients with colorectal cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S498028

Tian, H., Liu, Z., Zhang, Z., Zhang, L., Zong, Z., Liu, J., Ying, H., & Li, H. (2023). Clinical significance of fibrinogen and platelet to pre-albumin ratio in predicting the prognosis of advanced gastric cancer. Journal of Inflammation Research. https://doi.org/10.2147/JIR.S412033

Ying, H.-Q., Liao, Y.-C., Luo, Y.-R., Xiong, G., Huang, Y., Nie, R.-W., Xiong, C.-F., & Cheng, X.-X. (2021). Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naïve patients with advanced NSCLC. Pharmacological Research, 105734. https://doi.org/10.1016/j.phrs.2021.105734

Ying, H.-Q., You, X.-H., Liao, Y.-C., Sun, F., & Cheng, X.-X. (2021). High-grade inflammation attenuates chemosensitivity and confers poor survival of surgical stage III CRC patients. Frontiers in Oncology, 11, 580455. https://doi.org/10.3389/fonc.2021.580455

Liao, Y.-C., Ying, H.-Q., Huang, Y., Luo, Y.-R., Xiong, C.-F., Nie, R.-W., Li, X.-J., & Cheng, X.-X. (2021). Role of chronic inflammatory ratios in predicting recurrence of resected patients with stage I–III mucinous colorectal adenocarcinoma. Cancer Management and Research, 13, 303758. https://doi.org/10.2147/CMAR.S303758

Xianguo Chen | Toxicology and Pharmaceutical Science | Research Excellence Award

Published on by Research Awards

Prof. Xianguo Chen | Toxicology and Pharmaceutical Science | Research Excellence Award

Zhejiang University School of Medicine | China

Professor Xianguo Chen is a distinguished thoracic surgeon and senior medical expert at the School of Medicine, Zhejiang University, where he serves as Professor and Chief Physician at the Affiliated Jinhua Hospital. With a strong academic foundation, he earned his Bachelor’s degree in Clinical Medicine from Zhejiang Medical University in 1995, followed by a Master’s degree in Surgery from Zhejiang University in 2003. Over nearly three decades of clinical and research experience, Professor Chen has established himself as a leading figure in thoracic oncology, pulmonary diseases, and precision cancer therapeutics. His professional journey at Zhejiang University’s Affiliated Jinhua Hospital began in 1996, advancing from Physician to Attending Physician in 2000, Associate Chief Physician in 2006, and Chief Physician in 2011, reflecting his outstanding clinical expertise, leadership, and dedication to patient care. Professor Chen’s research interests lie at the intersection of thoracic surgery, molecular oncology, targeted cancer therapy, and tumor metabolism. He has led several high-impact scientific projects funded by provincial and municipal agencies. These include a major Jinhua Science and Technology Plan project investigating the regulatory effects of acacetin on SMYD2-mediated DNA damage repair inhibition, a provincial health science project exploring the mechanism by which KMT3C mediates osimertinib resistance in non-small cell lung cancer through ENO1-driven glycolysis, and an influential study on pulmonary nodule differentiation and lung cancer progression involving metabolomics and fecal microbiota transplantation. His research has made significant contributions to understanding tumor resistance mechanisms, novel biomarkers, and innovative therapeutic strategies for lung cancer. An accomplished scholar, Professor Chen has authored numerous publications in internationally recognized journals. His recent works include studies on miR-1293 and angiogenesis in lung adenocarcinoma, carbonic anhydrase 4 as a prognostic biomarker for NSCLC, identification of novel RET fusions and ALK translocations, and advancements in postoperative drainage techniques for lung cancer surgery. As first author, corresponding author, or co-corresponding author, his publications reflect his strong commitment to advancing thoracic oncology research. Beyond clinical and research excellence, Professor Chen plays a vital leadership role in several professional medical organizations. He serves as Vice Chairman of the Thoracic Surgery Branch of the Zhejiang Medical Association, Executive Vice Chairman of the Cardiothoracic Surgery Branch of the Jinhua Medical Association, and holds additional appointments in regional cancer prevention and thoracic surgery committees. Through his multifaceted contributions, Professor Xianguo Chen continues to shape the future of thoracic surgery and lung cancer research in China and beyond.

Profiles: Scopus | Orcid 

Featured Publications

Lou, Y., Xu, B., Huang, K., Li, X., Jin, H., Ding, L., Ning, S., & Chen, X. (2024). Knockdown of miR-1293 attenuates lung adenocarcinoma angiogenesis via Spry4 upregulation-mediated ERK1/2 signaling inhibition. Biochemical Pharmacology, 226, 116414.

Xu, B., Lou, Y., Xu, X., Li, X., Tian, X., Yu, Z., & Chen, X. (2023). Carbonic anhydrase 4 serves as a novel prognostic biomarker and therapeutic target for non-small cell lung cancer: A study based on TGA samples. Combinatorial Chemistry & High Throughput Screening, 26(14), 2527–2540.

Xu, X., Wang, H., Yu, Z., & Chen, X. (2022). A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: A case report. Journal of Cancer Research and Clinical Oncology, 148(7), 1825–1827.

Chen, X., Xu, B., Fu, F., Cai, K., & Yu, Z. (2021). A novel nonreciprocal/reciprocal ALK translocation causing ALK+ in NSCLC. Lung Cancer, 158, 162–163.

Li, X., Chen, X., He, S., & Chen, H. (2021). The application of pigtail catheters in postoperative drainage of lung cancer. Clinical Lung Cancer, 23(3), e196–e202.